• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis.复发/难治性多发性骨髓瘤患者接受idecabtagene vicleucel治疗后的后续抗骨髓瘤治疗：单中心分析
Blood Cancer J. 2022 Apr 19;12(4):66. doi: 10.1038/s41408-022-00662-0.
2
The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.美国用嵌合抗原受体 T 细胞疗法 cilta-cabtagene autoleucel 和 idecabtagene vicleucel 治疗成人复发性或难治性多发性骨髓瘤的经济负担。
BioDrugs. 2022 Nov;36(6):773-780. doi: 10.1007/s40259-022-00557-3. Epub 2022 Sep 27.
3
Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.伊达基奥仑赛（ide-cel）嵌合抗原受体 T 细胞疗法治疗复发/难治性多发性骨髓瘤。
Future Oncol. 2022 Jan;18(3):277-289. doi: 10.2217/fon-2021-1090. Epub 2021 Dec 2.
4
[New European approval: Idecabtagene vicleucel in relapsed and/or refractory myeloma after at least 3 lines of treatment].[欧洲新批准：idecabtagene vicleucel用于至少接受3线治疗后的复发和/或难治性骨髓瘤]
Bull Cancer. 2022 Feb;109(2):113-114. doi: 10.1016/j.bulcan.2021.10.007. Epub 2022 Jan 19.
5
FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma.FDA 批准概要：依达卡替（Idecabtagene Vicleucel）治疗复发/难治性多发性骨髓瘤。
Clin Cancer Res. 2022 May 2;28(9):1759-1764. doi: 10.1158/1078-0432.CCR-21-3803.
6
Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma.idecabtagene vicleucel（ide-cel，bb2121）治疗复发/难治性多发性骨髓瘤日本患者的 2 期结果。
Int J Hematol. 2023 May;117(5):729-737. doi: 10.1007/s12185-023-03538-6. Epub 2023 Jan 24.
7
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.伊达比星脂质体注射用多柔比星治疗复发/难治性多发性骨髓瘤
N Engl J Med. 2021 Feb 25;384(8):705-716. doi: 10.1056/NEJMoa2024850.
8
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.在治疗复发或难治性多发性骨髓瘤患者的 CARTITUDE-1 研究中比较 cilta-cabtagene autoleucel 与 idecabtagene vicleucel 的疗效结局的匹配调整间接比较。
Curr Med Res Opin. 2021 Oct;37(10):1779-1788. doi: 10.1080/03007995.2021.1953456. Epub 2021 Jul 23.
9
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.接受 idecabtagene vicleucel（ide-cel，bb2121）治疗后 2 年内患者报告体验的分析：来自 2 期 KarMMa 试验的纵向研究结果。多发性骨髓瘤复发或难治性。
Leuk Res. 2023 Jun;129:107074. doi: 10.1016/j.leukres.2023.107074. Epub 2023 Apr 3.
10
Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study.伊达比星、卡非佐米和 CD38 单克隆抗体 idecabtagene vicleucel 治疗复发/难治性多发性骨髓瘤患者的疗效和安全性：一项真实世界多中心研究。
Br J Haematol. 2024 Apr;204(4):1293-1299. doi: 10.1111/bjh.19302. Epub 2024 Jan 23.

引用本文的文献

1
CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies.嵌合抗原受体 T 细胞疗法在多发性骨髓瘤中的应用：当前的局限性与潜在策略。
Front Immunol. 2023 Feb 20;14:1101495. doi: 10.3389/fimmu.2023.1101495. eCollection 2023.
2
Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.在先前接受过抗B细胞成熟抗原治疗的多发性骨髓瘤患者中使用基于塞利尼索的治疗方案。
EJHaem. 2022 Sep 30;3(4):1270-1276. doi: 10.1002/jha2.572. eCollection 2022 Nov.
3
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.BCMA 靶向 CAR T 治疗后接受挽救性治疗的多发性骨髓瘤患者的干预措施和结局。
Blood. 2023 Feb 16;141(7):756-765. doi: 10.1182/blood.2022017848.
4
Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy.I-131 碘磷法辛治疗抗 BCMA 免疫治疗后复发/难治性多发性骨髓瘤的晚期患者。
Blood Cancer J. 2022 Sep 6;12(9):130. doi: 10.1038/s41408-022-00725-2.
5
CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges.多发性骨髓瘤患者的嵌合抗原受体T细胞疗法：当前证据与挑战
Blood Lymphat Cancer. 2022 Aug 29;12:119-136. doi: 10.2147/BLCTT.S327016. eCollection 2022.
6
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.嵌合抗原受体 T 细胞疗法在血液系统恶性肿瘤中的应用：当前的机遇与挑战。
Front Immunol. 2022 Jun 10;13:927153. doi: 10.3389/fimmu.2022.927153. eCollection 2022.

Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis.

作者信息

Parrondo Ricardo D, Sam Keren, Rasheed Ahsan, Alegria Victoria, Sher Taimur, Roy Vivek, Chanan-Khan Asher, Ailawadhi Sikander

机构信息

Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.

Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.

出版信息

Blood Cancer J. 2022 Apr 19;12(4):66. doi: 10.1038/s41408-022-00662-0.

DOI:10.1038/s41408-022-00662-0
PMID:35440072
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9019050/
Abstract
摘要